Leasure Audrey C, Qureshi Adnan I, Murthy Santosh B, Kamel Hooman, Goldstein Joshua N, Woo Daniel, Ziai Wendy C, Hanley Daniel F, Al-Shahi Salman Rustam, Matouk Charles C, Sansing Lauren H, Sheth Kevin N, Falcone Guido J
Department of Neurology, Yale School of Medicine, New Haven, Connecticut.
Zeenat Qureshi Stroke Institute, St Cloud, Minnesota.
JAMA Neurol. 2019 Aug 1;76(8):949-955. doi: 10.1001/jamaneurol.2019.1141.
Hypertension is the strongest risk factor for spontaneous intracerebral hemorrhage (ICH) involving deep brain regions, but it appears to be unknown if intensive blood pressure reduction in the acute care setting decreases hematoma expansion or improves outcomes in patients with deep ICH.
To determine whether intensive blood pressure reduction is associated with decreased risk of hematoma expansion and changes in 90-day modified Rankin Scale scores and if these associations are modified by the specific deep-brain nuclei involved.
DESIGN, SETTING, AND PARTICIPANTS: This study is an exploratory analysis of the Antihypertensive Treatment of Acute Cerebral Hemorrhage-2 international, multicenter randomized clinical trial, which was conducted from May 2011 to September 2015, enrolled eligible patients with primary ICH, and followed up with them for 90 days. Patients who had ICH and complete neuroimaging data were included in the analysis. Data analysis was completed from July 2018 to December 2018.
Participants were randomized to either intensive treatment (with a systolic blood pressure target of 110-139 mm Hg) or standard treatment (with a systolic blood pressure target of 140-179 mm Hg).
The main outcome was hematoma expansion, defined as an increase greater than 33% in hematoma volume between baseline and 24 hours. Functional outcome was evaluated 90 days after the ICH via the modified Rankin Scale.
Of 1000 trial participants, 870 (87.0%) had deep ICH, of whom 780 (89.7%) had complete neuroimaging data (of 336 thalamic and 444 basal ganglia hemorrhages). The baseline characteristics of the intensive and standard treatment groups remained balanced in this subgroup of the original study. Intensive treatment was associated with a decreased risk of hematoma expansion in univariable analysis (odds ratio [OR], 0.62 [95% CI, 0.43-0.87]; P = .006) and multivariable analysis (OR, 0.61 [95% CI, 0.42-0.88]; P = .009). This association was modified by the specific deep location of the ICH (OR, 0.44 [95% CI, 0.22-0.96]; interaction P = .02), with stratified analyses showing a reduction in risk of hematoma expansion with intensive vs standard treatment among basal ganglia ICH (OR, 0.44 [95% CI, 0.27-0.72]; P = .001) but not thalamic ICH (OR, 0.91 [95% CI, 0.51-0.64]; P = .76). Intensive treatment was not associated with an improvement in the modified Rankin Scale score distribution.
Compared with standard treatment, intensive blood pressure treatment was associated with reduced hematoma expansion in deep ICH, specifically among basal ganglia hemorrhages.
高血压是累及深部脑区的自发性脑出血(ICH)最强的危险因素,但在急性护理环境中强化降压是否能减少血肿扩大或改善深部ICH患者的预后尚不清楚。
确定强化降压是否与血肿扩大风险降低及90天改良Rankin量表评分变化相关,以及这些关联是否因所累及的特定深部脑核而有所改变。
设计、设置和参与者:本研究是对急性脑出血降压治疗-2国际多中心随机临床试验的探索性分析,该试验于2011年5月至2015年9月进行,纳入符合条件的原发性ICH患者,并对其进行90天随访。纳入有ICH且有完整神经影像学数据的患者进行分析。数据分析于2018年7月至2018年12月完成。
参与者被随机分为强化治疗组(收缩压目标为110 - 139 mmHg)或标准治疗组(收缩压目标为140 - 179 mmHg)。
主要结局是血肿扩大,定义为基线至24小时血肿体积增加超过33%。ICH发生90天后通过改良Rankin量表评估功能结局。
在1000名试验参与者中,870名(87.0%)有深部ICH,其中780名(89.7%)有完整神经影像学数据(336例丘脑出血和444例基底节出血)。在原研究的该亚组中,强化治疗组和标准治疗组的基线特征保持平衡。在单变量分析中,强化治疗与血肿扩大风险降低相关(优势比[OR],0.62[95%CI,0.43 - 0.87];P = 0.006),在多变量分析中也是如此(OR,0.61[95%CI,0.42 - 0.88];P = 0.009)。这种关联因ICH的特定深部位置而改变(OR,0.44[95%CI,0.22 - 0.96];交互作用P = 0.02),分层分析显示,在基底节ICH中,强化治疗与标准治疗相比,血肿扩大风险降低(OR,0.44[95%CI,0.27 - 0.72];P = 0.001),但在丘脑ICH中未降低(OR,0.91[95%CI,0.51 - 0.64];P = 0.76)。强化治疗与改良Rankin量表评分分布改善无关。
与标准治疗相比,强化血压治疗与深部ICH患者血肿扩大减少相关,特别是在基底节出血患者中。